News & Insights Search

Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical device regulation, and what we’re reading from around the web. This week, we learned that the Senate health committee has scheduled a vote to advance the nomination of President Trump’s pick for FDA commissioner, that the FDA has shelved a controversial drug voucher program, and that it has warned of risks of a rare eye condition resulting from the use of GLP-1 products.

Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical device regulation, and what we’re reading from around the web. This week, we’re looking at some of the ways the midterm election results could impact FDA over the next two years, starting with the confirmation prospects for President Trump’s pick for FDA commissioner and how Democrats may use their newfound oversight powers.

Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical device regulation, and what we’re reading from around the web. This week, FDA announced that its drug center and inspections office have agreed to a new concept of operations (ConOps) for coordinating inspections and other compliance activities, a senator released draft legislation that would give FDA new authorities for overseeing artificial intelligence (AI), and the agency has removed a boxed warning from the labels of estradiol patches.

Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical device regulation, and what we’re reading from around the web. This week, there are reports that some staff are concerned that a new HHS performance assessment could be a prelude to more layoffs, former FDA chiefs criticized last year’s mass firings, and more.

Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical device regulation, and what we’re reading from around the web. This week, the Department of Health and Human Services (HHS) announced an agency-wide initiative to study and address vaccine injuries, and the congressional committees that oversee FDA could see high turnover after the midterm elections.

Welcome to another installment of This Week at FDA, your weekly source for updates—big and small—on FDA, drug, and medical device regulation, and what we’re reading from around the web. This week, we learned that the White House’s nominee to lead FDA won’t get a confirmation vote until after the US November mid-term elections, that FDA seems to be restrengthening its advisory committee system, and more.

Welcome to another installment of This Week at FDA, your weekly source for updates—big and small—on FDA, drug, and medical device regulation and what we’re reading from around the web. This week, Senators grilled President Trump’s nominee to lead FDA during her confirmation hearing, and the agency published a rule to aimed at reducing animal testing.

This week, a Senate committee scheduled a hearing for President Trump’s nominee to lead FDA, new reporting sheds light on the agency’s hiring challenges, and the agency held two meetings to consider the use of psychedelic drugs for mental health disorders and the use of testosterone in menopausal women.

Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug, and medical device regulation, and what we’re reading from around the web. This week, FDA said it wants to conduct research into perceived barriers to enrolling women in pregnancy exposure registries, the agency announced priority review voucher fees for the next fiscal year, and it named permanent leaders to three of its product centers.

Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug, and medical device regulation, and what we’re reading from around the web. Several top FDA officials outlined steps they are taking to bolster clinical trial inspections, especially for foreign trials, the agency is seeking input on botanical drugs, and the Department of Health and Human Services (HHS) has issued a new emergency use authorization declaration for military purposes.